Trump may be mystery patient in odd case of 79yo getting experimental obesity drug
Public notice of a single "compassionate use" case is odd in every way.
Signal weather
Rising
Momentum is building quickly, so this card is a good early entry point into the topic.
In an extremely odd case, a single 79-year-old patient was granted early access to Eli Lilly's powerful, still-experimental obesity drug retatrutide through the Food and Drug Administration's "compassionate use" program—raising immediate questions if that sole patient is President Donald Trump, according to a report by Stat News. Lilly's retatrutide is a highly anticipated next-generation obesity drug that targets GIP and glucagon hormones in addition to GLP-1. It is currently in late-stage trials to treat obesity, diabetes, sleep apnea, and other conditions. Data from a Phase 3 trial that Lilly released in May indicates that patients with obesity (but without diabetes) who took the drug for 80 weeks lost 28 percent of their weight, an amount comparable to bariatric surgery. Millions of Americans with obesity are eager to get the drug, with options being limited so far to enrolling in a clinical trial or trying to obtain it by dodgy methods. Read full article Comments
Stay on the signal
Follow Trump may be mystery patient in odd case of 79yo getting experimental obesity drug
Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.
Story map
Understand this topic fast
A quick entry into the story: why it matters now, who is involved, and where to go next for context.
Why it matters now
Topic constellation
Open the live map for this story
See which entities, story threads, sources, and follow-up articles shape this story right now.
Click nodes to continue
Story timeline
Continue with this story
A short sequence of events and follow-up stories to understand the arc quickly.
How reliable this looks
Signal and trust for Ars Technica
This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.
Reliability
92
Freshness
100
Sources in storyline
1
Related articles
More stories that share tags, source, or category context.
A curious crossover: The Toyota C-HR review
Although it's on the smaller side, this electric vehicle is not very chill.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
ABC asks viewers to protest FCC attempt to "control who is allowed" on The View
"The FCC wants to control who is allowed on the show," ABC ad tells viewers.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Early land animals skipped the tadpole phase
Current amphibian development may not have been typical of early land vertebrates.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
How GPT-5 helped immunologist Derya Unutmaz solve a 3-year-old mystery
GPT-5 Pro helped solve a 3-year-old immunology mystery, offering insights into T cell behavior. The breakthrough could support cancer and autoimmune research.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
More from Ars Technica
Fresh reporting and follow-up coverage from the same newsroom.
A curious crossover: The Toyota C-HR review
Although it's on the smaller side, this electric vehicle is not very chill.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
ABC asks viewers to protest FCC attempt to "control who is allowed" on The View
"The FCC wants to control who is allowed on the show," ABC ad tells viewers.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Early land animals skipped the tadpole phase
Current amphibian development may not have been typical of early land vertebrates.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Everyone pays the price as patent holders on seeds stifle innovation
The US is one of a handful of countries that allow patents on plant varieties.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.